Experience with a higher impedance, fixed helix, steroid-eluting pacing lead. The SWEET PICOTIP Rx Study Group.
A higher impedance, steroid-eluting pacing lead was studied in a multicenter trial. A total of 132 leads were implanted in 61 patients and the electrical characteristics were compared with historical controls. The study lead had a lower pacing threshold at 3 months, 0.72 +/- 0.33 versus 1.29 +/- 0.82 in the atrium and 0.71 +/- 0.25 versus 1.52 +/- 0.52 in the ventricle (P < 0.01 for both). Impedance was significantly higher in the study lead, 923 +/- 133 versus 719 +/- 109 in the atrium and 980 +/- 235 versus 664 +/- 104 in the ventricle (P < 0.01 for both). Sensing was similar for both leads. The study lead's higher impedance values and low pacing thresholds combine to reduce pacing system energy requirements.
Giudici
M C
MC
Division of Cardiology, Genesis Medical Center, Davenport, Iowa, USA. Giudici@CVMedPC.com
Lee
M
M
Higgins
S
S
West
G R
GR
Moeller
A K
AK
Decker
J B
JB
D000368:Aged; D001145:Arrhythmias, Cardiac / Q000628:therapy; D016022:Case-Control Studies; D003907:Dexamethasone / Q000008:administration & dosage / Q000031:analogs & derivatives; D017097:Electric Impedance; D004567:Electrodes, Implanted; D004867:Equipment Design; D005260:Female; D006801:Humans; D008297:Male; D010138:Pacemaker, Artificial
D003907:Dexamethasone; C018038:dexamethasone acetate